止血劑市場規模、佔有率及成長分析（按類型、應用、最終用戶和地區分類）－2026-2033年產業預測

全球止血劑市場規模預計在 2024 年達到 80.3 億美元，從 2025 年的 87.4 億美元成長到 2033 年的 171.5 億美元，在預測期（2026-2033 年）內複合年成長率為 8.8%。

出血性疾病和與人口老化相關的慢性疾病日益增多，推動了對先進止血劑的需求。此外，全球外科手術的普及也促進了這個市場的發展，對有效止血解決方案的需求日益成長。同時，交通事故導致的嚴重出血事件頻繁，也使得這些止血劑的需求更加迫切。包括機器人輔助手術在內的外科技術創新可望進一步推動這項需求。然而，手術費用高昂和報銷政策不合理等挑戰可能會阻礙市場成長。此外，新興市場和開發中國家對止血劑最新技術進展的認知和了解不足，也可能阻礙市場的整體擴張。

全球止血劑市場促進因素

全球外科手術數量的不斷成長顯著增加了術中出血併發症的發生率，這也是全球止血劑市場的主要驅動力。目前，市面上已有多種先進的醫療設備用於促進手術中的止血。據估計，相當一部分用於輸血的紅血球專門用於外科手術，證實了在手術過程中控制出血的重要性。有鑑於此，許多外科醫生選擇使用止血劑來最大限度地降低術中出血的風險，從而產生了對止血產品的強勁需求，並推動了市場成長。

限制全球止血劑市場的因素

全球止血劑市場面臨許多限制因素，包括各種臨床限制，這些限制阻礙了止血治療方法的廣泛應用。無法控制的出血仍然是一個重要問題，在某些情況下會限制止血劑的療效。雖然這些產品能夠改善手術過程中的出血控制並降低感染風險，但其高成本仍然是推廣應用的一大障礙。此外，某些特定手術通常需要專用手術器械，這也限制了止血劑的應用範圍。儘管技術不斷進步，但這些臨床限制仍限制這些重要產品在醫療領域的應用。

全球止血劑市場趨勢

全球止血劑市場正經歷顯著成長，其主要驅動力在於解決失控性出血的緊急應變需求。失控性出血是軍民兩棲環境導致死亡的主要原因之一。超過30%的創傷死亡病例歸因於過度出血，因此，急診和外科手術中對高效止血劑的需求激增。這些止血劑在創傷治療中發揮著至關重要的作用，透過減少低體溫、感染疾病、器官衰竭和酸中毒等併發症，有助於提高患者的存活率。隨著人們對止血劑救命功效的認知不斷提高，以及止血技術的持續進步，預計該市場將穩步擴張。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球止血劑市場規模（按類型和複合年成長率分類）（2026-2033 年）

• 基於凝血酶的止血劑
• 明膠基止血劑
• 膠原蛋白蛋白止血劑
• 氧化再生纖維素止血劑
• 複方止血劑
• 纖維蛋白膠
• 其他

全球止血劑市場規模（按治療方法和複合年成長率分類）（2026-2033 年）

• 心血管系統
• 一般外科
• 胃腸外科手術
• 神經外科
• 其他

全球止血劑市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 手術中心
• 護理機構
• 其他

全球止血劑市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Johnson & Johnson（USA）
• Pfizer Inc.（USA）
• Baxter International Inc.（USA）
• Becton, Dickinson and Company（USA）
• Medtronic plc（Ireland）
• Stryker Corporation（USA）
• Sanofi SA（France）
• CSL Limited（Australia）
• Zimmer Biomet Holdings, Inc.（USA）
• Teleflex Incorporated（USA）
• CryoLife, Inc.（USA）
• Integra LifeSciences Holdings Corporation（USA）
• Mallinckrodt Pharmaceuticals（UK）
• B. Braun Melsungen AG（Germany）
• Terumo Corporation（Japan）
• Smith & Nephew plc（UK）
• Haemonetics Corporation（USA）
• Ethicon, Inc.（USA）
• The Medicines Company（USA）
• Anika Therapeutics, Inc.（USA）

結論與建議

Global Hemostatic Agents Market size was valued at USD 8.03 Billion in 2024 and is poised to grow from USD 8.74 Billion in 2025 to USD 17.15 Billion by 2033, growing at a CAGR of 8.8% during the forecast period (2026-2033).

The demand for advanced hemostatic agents is rising due to an increasing prevalence of bleeding disorders and chronic diseases among the aging population. The expansion of surgical procedures globally further drives this market, necessitating effective hemostatic solutions. Additionally, the high incidence of severe bleeding from road accidents contributes to the urgency for these agents. Innovations in surgical techniques, including robotic-assisted procedures, are expected to bolster this demand. However, market growth may face challenges, such as the high costs associated with surgical treatments and unfavorable reimbursement policies. Moreover, limited awareness and understanding of the latest technological advancements in hemostatic agents in emerging and developing countries could hinder overall market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hemostatic Agents market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hemostatic Agents Market Segments Analysis

Global Hemostatic Agents Market is segmented by Type, Treatment, End User and region. Based on Type, the market is segmented into Thrombin Based Hemostats, Gelatin Based Hemostats, Collagen Based Hemostats, Oxidized Regenerated Cellulose Based Hemostats, Combination Hemostats, Fibrin Sealants and Others. Based on Treatment, the market is segmented into Cardiovascular, General Surgery, Digestive Surgery, Neurosurgery and Others. Based on End User, the market is segmented into Hospitals, Surgery Centers, Nursing Homes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hemostatic Agents Market

The increasing volume of surgical procedures worldwide has significantly contributed to the heightened prevalence of bleeding complications during operations, serving as a primary catalyst for the global Hemostatic Agents market. Presently, there is an extensive array of advanced medical devices designed to facilitate hemostasis in surgical settings. Estimates indicate that a substantial proportion of transfused red blood cells are utilized specifically in surgical contexts, underscoring the critical nature of managing bleeding during these interventions. This reality has led to a robust demand for hemostatic products, as many surgeons opt for these solutions to minimize the risks associated with bleeding during surgeries, thus driving market growth.

Restraints in the Global Hemostatic Agents Market

The Global Hemostatic Agents market faces significant restraints due to various clinical limitations that hamper the widespread adoption of these treatments. Uncontrolled bleeding remains a critical concern, restricting the effectiveness of hemostatic agents in certain situations. Although these products provide improved outcomes in managing bleeding during surgical procedures and mitigate infection risks, their high costs pose barriers to accessibility. Furthermore, specific surgical instruments are often required for particular procedures, which can also limit the applications of hemostatic agents. Despite advancements in technology, these clinical constraints continue to constrain the utilization of these crucial products within the medical field.

Market Trends of the Global Hemostatic Agents Market

The Global Hemostatic Agents market is experiencing significant growth driven by the urgent need to address uncontrolled hemorrhage, a leading cause of mortality in both military and civilian settings. As more than 30% of traumatic deaths are attributed to excessive bleeding, the demand for effective hemostatic drugs in emergency and surgical environments is surging. These agents play a vital role in trauma care, mitigating complications such as hypothermia, infections, organ failure, and acidosis, thus enhancing patient survival rates. As awareness of their life-saving potential increases and advancements in hemostatic technology continue, the market is poised for robust expansion.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hemostatic Agents Market Size by Type & CAGR (2026-2033)

• Market Overview
• Thrombin Based Hemostats
• Gelatin Based Hemostats
• Collagen Based Hemostats
• Oxidized Regenerated Cellulose Based Hemostats
• Combination Hemostats
• Fibrin Sealants
• Others

Global Hemostatic Agents Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Cardiovascular
• General Surgery
• Digestive Surgery
• Neurosurgery
• Others

Global Hemostatic Agents Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Surgery Centers
• Nursing Homes
• Others

Global Hemostatic Agents Market Size & CAGR (2026-2033)

• North America (Type, Treatment, End User)
  • US
  • Canada
• Europe (Type, Treatment, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zimmer Biomet Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teleflex Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CryoLife, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Integra LifeSciences Holdings Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Smith & Nephew plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haemonetics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ethicon, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• The Medicines Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anika Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations